US Bancorp DE Grows Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

US Bancorp DE boosted its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 2,084.0% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 32,934 shares of the biopharmaceutical company’s stock after buying an additional 31,426 shares during the quarter. US Bancorp DE’s holdings in ACADIA Pharmaceuticals were worth $507,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. boosted its position in shares of ACADIA Pharmaceuticals by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 31,903 shares of the biopharmaceutical company’s stock worth $491,000 after purchasing an additional 12,493 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in ACADIA Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 1,066 shares in the last quarter. Garrison Point Advisors LLC purchased a new stake in ACADIA Pharmaceuticals during the third quarter valued at $163,000. Values First Advisors Inc. purchased a new stake in ACADIA Pharmaceuticals during the third quarter valued at $27,000. Finally, Allspring Global Investments Holdings LLC raised its stake in ACADIA Pharmaceuticals by 11.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 121,625 shares of the biopharmaceutical company’s stock valued at $1,871,000 after purchasing an additional 12,787 shares in the last quarter. 96.71% of the stock is currently owned by institutional investors.

ACADIA Pharmaceuticals Trading Up 3.5 %

ACAD opened at $18.27 on Tuesday. ACADIA Pharmaceuticals Inc. has a 12-month low of $14.15 and a 12-month high of $32.59. The firm has a market capitalization of $3.03 billion, a PE ratio of 23.42 and a beta of 0.38. The firm has a 50 day moving average of $15.48 and a two-hundred day moving average of $15.98.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.06. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 27.29%. The company had revenue of $250.40 million during the quarter, compared to analyst estimates of $248.83 million. During the same period last year, the firm posted ($0.40) EPS. ACADIA Pharmaceuticals’s revenue for the quarter was up 18.3% compared to the same quarter last year. As a group, analysts predict that ACADIA Pharmaceuticals Inc. will post 0.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on ACAD. Royal Bank of Canada decreased their price target on shares of ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Cantor Fitzgerald reduced their price target on shares of ACADIA Pharmaceuticals from $37.00 to $28.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. UBS Group dropped their target price on shares of ACADIA Pharmaceuticals from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Six equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, ACADIA Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.56.

Insider Activity

In other news, COO Brendan Teehan sold 9,534 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $15.28, for a total transaction of $145,679.52. Following the completion of the transaction, the chief operating officer now directly owns 52,177 shares of the company’s stock, valued at $797,264.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Mark C. Schneyer sold 9,733 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $15.28, for a total transaction of $148,720.24. Following the completion of the transaction, the chief financial officer now directly owns 43,735 shares of the company’s stock, valued at $668,270.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Brendan Teehan sold 9,534 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $15.28, for a total transaction of $145,679.52. Following the transaction, the chief operating officer now directly owns 52,177 shares of the company’s stock, valued at approximately $797,264.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 51,014 shares of company stock valued at $779,494 in the last three months. 28.30% of the stock is currently owned by corporate insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.